What type of study is this?

Severity‐Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19‐Targeted CAR T‐Cell Therapy

View Full Paper

Ask AI

Bookmark

Authors

Case-control study reveals significant elevation of biomarkers in patients with moderate–severe ICANS, highlighting diagnostic potential.

Moderate–severe ICANS correlates with elevated serum neurofilament levels post-infusion, indicating neuroaxonal damage.
Among 54 patients developing ICANS, those with grade ≥ 2 had significant z-scores of 2.33 compared to 1.72 in mild or absent ICANS cases.
This case-control analysis utilized z-score calculations of sNfL concentrations to assess neurotoxicity in NHL patients receiving CAR T-cell therapy.
Elevated sNfL levels may serve as important biomarkers for the early assessment of ICANS severity, necessitating further validation.

Vilaseca et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Case-control study reveals significant elevation of biomarkers in patients with moderate–severe ICANS, highlighting diagnostic potential.

Moderate–severe ICANS correlates with elevated serum neurofilament levels post-infusion, indicating neuroaxonal damage.
Among 54 patients developing ICANS, those with grade ≥ 2 had significant z-scores of 2.33 compared to 1.72 in mild or absent ICANS cases.
This case-control analysis utilized z-score calculations of sNfL concentrations to assess neurotoxicity in NHL patients receiving CAR T-cell therapy.
Elevated sNfL levels may serve as important biomarkers for the early assessment of ICANS severity, necessitating further validation.

Vilaseca et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark